Process engineering and pharmaceutical manufacturing technologies


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/76921/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
In recent years, the pharmaceutical industry is going through a period of exceptional changes, where emerging-market expansion and technology advances have increased sector growth. Many new drug candidates found in the drug discovery pipeline generally have poor physico-chemical and biopharmaceutical properties, such as poor solubility or low chemical compatibility, which severly limits their oral bioavailability and thus therapeutic performance. The reduction in the numbers of new molecules coming to market along with the expiry of the existing patents is also forcing the pharmaceutical industry to invest in and embrace new technologies that can save both costs and time for manufacture. One timely solution to the growing need can be the exploitation of continuous manufacturing and process engineering with better controls, reproducibility, low labour and production cost. Recently, implementation of process analytical tools (PAT) under the Quality by Design (QbD) paradigm has attracted a strong interest by pharmaceutical scientists as well as the regulatory agencies across the globe. The ultimate aims of these QbD approaches are being the science-based design and development of formulation and manufacturing processes for the predefined product quality objects.

As the guest editors of this special issue of Drug Delivery and Translational Research, we are pleased to introduce our theme issue on “Process Engineering and Pharmaceutical Manufacturing Technologies”. This theme issue contains two distinct parts: the first part focuses on recent developments of various novel formulations via continuous manufacturing, i.e. HME, whereas the second part focuses on various aspects of emerging pharmaceutical technologies and and their contributions to drug delivery. Timely and authoritative, this issue containing 15 original research articles and 5 critical review articles that will be of significant interest to readers across both industry and academia.

The paper authored by Wesholowski et al., reported the application of an in-line UV/Vis spectrometer as a PAT tool for early development of Twin-Screw-Extruder and the performance tested in accordance to the ICH Q2 – guideline. In this study, the authors explored two APIs (carbamazepine and theophylline) with one polymer matrix (copovidone) to quantify the drug loading in the formulation. Similarly, Omar et al., studied the temperature of the
ribbon via an online thermal camera which was used to explain the differences in ribbon properties at varying process parameters. The authors found that the increase in the roller speed during roller compaction somehow decreased the width of the ribbon while increasing the percentage of fines in the product. In a separate study, Al Asady et al., studied the plastic deformation of various primary particles via roller compaction process by determining two mechanical properties; the nano-indentation hardness and the viscoelasticity of the primary powder. The authors also identified that the plastic deformation of the material had the potential to provide an indication for the ability of the primary powder to produce a good ribbon. Desai et al., implemented a Design of Experiments (DoE), a tool of Quality by Design (QbD) paradigm, in order to evaluate the interaction of input variables (compression force, tablet punch configuration and DC filler) affecting the response factors (tablet hardness and capping rating) during the manufacture of pharmaceutical tablets. Similarly, Pawar et al., investigated the dissolution rate performance of amorphous solid solutions of a poorly water-soluble drug, efavirenz (EFV), in amorphous polymeric matrices by adopting a Box-Behnken design of experiment (DoE) approach. Box Behnken factorial design was conducted to evaluate the effect of independent variables such as polymer ratio, HME screw speed, and processing temperature on responses such as solubility, dissolution rate.

In another study, Majumder et al., explored the first case of the implementation of solution calorimetry (SolCal) in order to determine the amorphous content of crystalline drug in the amorphous granules prepared via emerging single step continuous twin-screw dry granulations (TSG). The authors claimed to have made an attempt to interrelate the findings from the SolCal to that of the release of the drug. Li et al., presented a new polymer blend system of ethylcellulose (EC) with poly(vinylpyrrolidone-co-vinyl acetate) (PVP VA64) for sustained release prepared via HME whereas Sawant et al., used the use of Eudragit®S100 and Eudragit®L100 alone or in combination with release-modifying agent namely. PolyoxTM WSR 303 and Eudragit®L100-55 for delayed release dosage forms via HME processing. A critical review in the area of sustained release dosage forms authored by Feng et al., provides a comprehensive report on the formulation composition and processing conditions of twin-screw extrusion and how these factors affect the drug release properties of sustained-release dosage forms whereas Maincent et al., reviewed the details of the challenges and the formulation approaches employed during the manufacture of sustained-release amorphous solid dispersions (ASDs). Another review paper authored by Chavan et al., describes various continuous manufacturing methods for co-crystal production, along with in-line monitoring during cocrystal production, emphasizing on Process Analytical Technology (PAT) as well as the scale up issues of continuous and batch co-crystallization and other suitable techniques for pharmaceutical scale up. Brunauth et al., critically discuss the optimization of the pharmaceutical milling process through design-space development, theoretical and empirical modelling, and monitoring of critical quality attributes.

Ahmed et al., developed a calcium alginate (CA) wafer dressings by lyophilization of hydrogels to deliver ciprofloxacin (CIP) directly to the wound site of infected diabetic foot ulcers (DFUs) whereas Molina et al., utilised optimised spray drying process to modify the physicochemical/mechanical properties of particles of lactose-based particles to enhance the aerosolisation performance of salbutamol sulphate in the presence of leucine in the spray dried powders. Trivedi et al., reported a study that considers the in vitro uptake and release characteristics of the binary theophylline-smectite system with a maximum uptake of 67 ± 2
In a separate study, the group developed polycaprolactone (PCL) nanoparticles via supercritical fluid extraction of emulsions (SFEE) using supercritical carbon-dioxide (scCO2). Jara et al., studied the process to yield monomodal and uniform polymeric nano-particles via a nanoprecipitation method. To further identify key variables and their interactions, the authors used artificial neural networks (ANN) to investigate the multiple variables which influence the process. In another study, Fritz et al., developed a novel lipid-core micelle (LCM) as a nanocarrier to encapsulate a poorly water-soluble drug, nifedipine (NFD), by hot-melt emulsification, a low-energy method. Haj-Ahmad et al., designed, engineered and utilised a novel multi-tip emitter (MTE) devices for potential up-scaled electrohydrodynamic atomisation (EHDA) an emerging technique for the production of micron and nano-scaled particles of ketoprofen – a model drug, by comparison with a conventional single needle system. An exhaustive review paper authored by Tarbox et al., highlights recent developments in microneedle coating and manufacturing techniques, including micro-milling, atomized spraying, inkjet printing, drawing lithography, droplet-born air blowing, electro-drawing, continuous liquid interface production, 3-D printing, and polyelectrolyte multilayers coating.

The guest editors of this theme issue would also like to thank the authors for their valuable contributions and input without which this theme issue would not have been possible. It is through their persistent and collective efforts that such a comprehensive and insightful theme issue was created.